The continuum of GERD complications

Cleveland Clinic Journal of Medicine

Volumn 70, Issue SUPPL. 5, 2003, Pages

  Fennerty, M Brian ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDITY; BARRETT ESOPHAGUS; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; REFLUX ESOPHAGITIS; REVIEW; ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; CHILD; ESOPHAGOSCOPY; ESOPHAGUS TUMOR; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; MONITORING; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; SEX RATIO;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; BARRETT ESOPHAGUS; BIOPSY, NEEDLE; CHILD; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; ESOPHAGOGASTRIC JUNCTION; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 10644238185     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.suppl_5.s33     Document Type: Review

References (53)

1. Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999; 72:81-92.
2. Richter J, Falk GW. Barrett's esophagus and adenocarcinoma: the need for a consensus conference. J Clin Gastroenterol 1996; 23:88-90.
3. Winters C, Spurting TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92:118-124.
4. Dodds WJ, Hogan WJ, Helm JF, Dent J. Pathogenesis of reflux esophagitis. Gastroenterology 1981; 81:376-394.
5. Armstrong D. Endoscopic evaluation of gastroesophageal reflux disease. Yale J Biol Med 1999; 72:93-100.
6. Voutilainen M, Sipponen P, Mecklin J, Juhola M, Färkkilä M. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000; 61:6-13.
7. Johanson JF. Epidemiology of esophageal and supraesophageal reflux injuries. Am J Med 2000; 108(suppl 4a):99-103.
8. Collen MJ, Abdulian JD, Chen YK. Gastroesophageal disease in the elderly: more severe disease that requires aggressive therapy. Am J Gastroenterol 1995; 90:1053-1057.
9. Yeh C, Hsu CT, Ho AS, Sampliner RE, Fass R. Erosive esophagitis and Barrett's esophagus in Taiwan: a higher frequency than expected. Dig Dis Sci 1997; 42:702-706.
10. Tytgat GNJ, Nio CY. The medical therapy of reflux oesophagitis. Baillieres Clin Gastroenterol 1987; 1:791-807.
11. Orr WC, Allen ML, Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol 1994; 89:509-512.
12. Venables TL, Newland RD, Patel AC, et al. Omeprarole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32:965-973.
13. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45:172-180.
14. Lieberman DA, Oehlke M, Helfand M, and the GORGE Consortium. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol 1997; 92:1293-1297.
15. DeVault KR. Methods of GERD diagnosis (chapter 5). In: Richter JE, ed. GI Masters Program: Healing Horizons in Acid Reflux Disease. Cleveland, Ohio: The Cleveland Clinic Foundation Center for Continuing Education; 2003:123-154.
16. El-Serag HB, Sonnenberg A. Associations between different forms of gastro-oesophageal reflux disease. Gut 1997; 41:594-599.
17. El-Serag HB, Sonnenberg A. Outcome of erosive reflux esophagitis after Nissen fundoplication. Am J Gastroenterol 1999; 94: 1771-1776.
18. Kuo W, Kalloo A. Reflux strictures of the esophagus. Gastrointest Endosc Clin N Am 1998; 8:273-281.
19. Richter JE. Peptic strictures of the esophagus. Gastroenterol Clin 1999; 28:875-891.
20. Murphy PP, Ballinger PJ, Massey BT, Shaker R, Hogan WJ. Discrete ulcers in Barrett's esophagus: relationship to acute gastrointestinal bleeding. Endoscopy 1998; 30:367-370.
21. Spechler SJ. Barrett's esophagus. In: McNally PR, ed. GI/Liver Secrets. Philadelphia: Hanley & Belfus, Inc.; 1996:50-58.
22. Coppola D, Karl R. Barrett's esophagus and Barrett's-associated neoplasia: etiology and pathologic features. Cancer Control 1999; 6:21-27.
23. Csendes A, Smok G, Burdiles F, et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastrocsophageal reflux. Dis Esophagus 2000; 13:5-11.
24. Falk G. Unresolved issues in Barrett's esophagus in the new millennium. Dig Dis 2000; 18:27-42.
25. Oberg S, Clark G, DeMeester T. Barrett's esophagus: update of pathophysiology and management. Hepatogastroenterology 1998; 45:1348-1356.
26. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111:1192-1199.
27. Cameron A, Lomboy C. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103:1241-1245.
28. Cameron A, Zinsmeister A, Ballard D, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus: comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99:918-922.
29. Azuma N, Endo T, Arimura Y, et al. Prevalence of Barrett's esophagus and expression of mucin antigens detected by a panel of monoclonal antibodies in Barrett's esophagus and esophageal adenocarcinoma. J Gastroenterol 2000; 35:583-592.
30. Adulaumi D, Jankowski J. Barrett's esophagus: an overview of the molecular biology. Dis Esophagus 1999; 12:177-180.
31. Sharma P. Recent advances in Barrett's esophagus: short-segment Barrett's esophagus and cardia intestinal metaplasia. Semin Gastrointest Dis 1999; 10:93-102.
32. DeMeester S, DeMeester T. The diagnosis and management of Barrett's esophagus. Adv Surg 1999; 33:29-68.
33. Weston AP, Krmpotich P, Makdisi WF, et al. Short-segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. Am J Gastroenterol 1996; 91:981-986.
34. Sampliner R. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93:1028-1032.
35. Kubba AK, Watson A. Role of p53 assessment in management of Barrett's esophagus. Dig Dis Sci 1999; 44:659-667.
36. Levine D. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin North Am 1997; 26:613-634.
37. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalosvki M. Prospective long-term endoscopic and histological follow-up of short-segment Barrett's esophagus: comparison with traditional long-segment Barrett's esophagus. Am J Gastroenterol 1997; 92:407-413.
38. Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathologic study. Am J Gastroenterol 1997; 92:586-591.
39. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. New Engl J Med 1999; 340:825-831.
40. Burdick JS. Esophageal cancer prevention, cure, and palliation. Semin Gastrointest Dis 2000; 11:124-133.
41. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049-2053.
42. National Cancer Institute. SEER Cancer Statistics Review, 1973-1996. Available at: http://seer.cancer.gov/faststats/html/inc_colorect.html.
43. Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000; 133:165-175.
44. Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg 2000; 190:562-573.
45. Chow W, Finkle WD, McLaughin JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274:474-477.
46. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92:212-215.
47. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94:2037-2042.
48. Menke-Pluymers MB, Hop WC, Dees J, et al. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett's) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993; 72:1155-1158.
49. Hamilton SR, Smith RRL, Cameron JL. Prevalence and characteristics of Barrett's esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol 1988; 19:942-948.
50. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999; 94:3413-3419.
51. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk in adenocarcinoma. J Natl Cancer Inst 2000; 92:1316-1321.
52. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102:1212-1219.
53. Cohen S, Parkman HP. Heartburn-a serious symptom. N Engl J Med 1999; 340:878-879.